References
- Harrell Jr RE, Simmons HF. Pleuropulmonary tularemia: successful treatment with erythromycin. South Med J 1990; 83: 1363–4.
- Berardi VP, Weeks KE, Steere AC. Serodiagnosis of early Lyme disease; evaluation of IgM and IgG antibody responses by using an antibody capture enzyme immunoassay. J Infect Dis 1988; 158: 754–60.
- Molloy PJ, Berardi VP, Persing DH, Sigal LH. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A Lyme disease vaccination. Clin Infect Dis 2000; 31: 42–7.
- Krause PJ, Telford 3rd SR, Ryan R, Conrad PA, Wilson M, Thomford JW, et al. Diagnosis of babesiosis: evaluation of a serologic test for the detection of babesia microti antibody. J Infect Dis 1994; 169: 923–6.
- Lodes MJ, Mohamath R, Reynolds LD, McNeill P, Kolbert CP, McNeill P, et al. Serodiagnosis of human granulocytic ehrlichiosis by using novel combinations of immunoreactive recombinant proteins. J Clin Microbiol 2001; 39: 2466–76.
- Persing DH, Mathiesen D, Marshall WF, Telford SR, Spielman A, Thomford JW, et al. Detection of Babesi microti by polymerase chain reaction. J Clin Microbiol 1992; 30: 2097–103.
- Edelman DC, Dumler JS. Evaluation of an improved PCR diagnostic assay for human granulocytic ehrlichiosis. Mol Diagn 1996; 1: 41–9.
- Phillips CB, Liang MH, Sangha O, Wright EA, Fossel AH, Lew RA, et al. Lyme disease and preventive behaviors in residents of Nantucket Island, Massachusetts. Am J Prev Med 2001; 20: 219–24.
- Ruebush 2nd TK, Juranek DD, Spielman A, Piesman J, Healy GR. Epidemiology of human babesiosis on Nantucket Island. Am J Trop Med Hyg 1981; 30: 937–41.
- Feldman KA, Enscore RE, Lathrop SL, Matyas BT, McGuill M, Schriefer ME, et al. An outbreak of primary pneumonia tularemia on Martha’s Vineyard. N Engl J Med 2001; 345: 1601–6.
- Chen SM, Dumler JS, Bakken JS, Walker DH. Identification of a granulocytotrophic ehrlichia species as the etiologic agent of human disease. J Clin Microbiol 1994; 32: 589–95.
- Bakken JS, Dumler JS. Human granulocytic ehrlichiosis. Clin Infect Dis 2000; 31: 554–60.
- Human granulocytic ehrlichiosis—New York, 1995. MMWR Morb Mortal Wkly Rep 1995; 44: 593–5.
- Belongia EA, Gale CM, Reed KD, Mitchell PD, Vandermause M, Finkel MF, et al. Population-based incidence of human granulocytic ehrlichiosis in northwestern Wisconsin, 19971999. J Infect Dis 2001; 184: 1470–4.
- Walls JJ, Caturegli P, Bakken JS, Asanovich KM, Dumler JS. Improved sensitivity of PCR for diagnosis of human granulocytic ehrlichiosis using epank1 genes of Ehrlichia phagoc-tyophilla-group ehrlichia. J Clin Microbiol 2000; 38: 354–6.
- Bakken JS, Haller I, Riddell D, Walls JJ, Dumler JS. The serological response of patients infected with the agent of human granulocytic ehrlichiosis. Clin Infect Dis 2002; 34: 22–7.
- Buitrago MI, Ijdo JW, Rinaudo P, Simon H, Copel J, Gadbaw J, et al. Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin. Clin Infect Dis 1998; 27: 213–5.
- Klein MB, Curtis M, Goodman N. Antibiotic susceptibility of the newly cultivated agent of human granulocytic ehrlichiosis: promising activity of quinolones and rifamycins. Antimicrob Agents Chemother 1997; 41: 76–9.
- Horowitz HW, Kilchevsky E, Haber S. Perinatal transmission of the agent of human granulocytic ehrlichiosis. N Engl J Med 1998; 339: 375–8.